Cidara Therapeutics, Inc. financial data

Symbol
CDTX on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
6310 Nancy Ridge Drive, Suite 101, San Diego, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
K2 THERAPEUTICS, INC. (to 2/4/2015)
Latest financial report
10-K - Q4 2024 - Mar 6, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 293 % +135%
Quick Ratio 8.19 %
Debt-to-equity 53.8 % -99.3%
Return On Equity -173 % +93.5%
Return On Assets -113 % -246%
Operating Margin -13.8K % -11784%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 11M shares -88%
Common Stock, Shares, Outstanding 10.9M shares +142%
Entity Public Float 53.3M USD -46.8%
Common Stock, Value, Issued 1K USD 0%
Weighted Average Number of Shares Outstanding, Basic 6.35M shares +45.3%
Weighted Average Number of Shares Outstanding, Diluted 6.35M shares +45.3%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 1.28M USD -94.5%
Revenue from Contract with Customer, Excluding Assessed Tax 2.83M USD
Research and Development Expense 71.9M USD +95.5%
General and Administrative Expense 13.6M USD -26.5%
Operating Income (Loss) -176M USD -551%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -15.5M USD -303%
Income Tax Expense (Benefit) 0 USD -100%
Net Income (Loss) Attributable to Parent -170M USD -641%
Earnings Per Share, Basic -26.8 USD/shares -410%
Earnings Per Share, Diluted -26.8 USD/shares -410%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 190M USD +431%
Accounts Receivable, after Allowance for Credit Loss, Current 1.69M USD -88%
Inventory, Net 7.27M USD
Assets, Current 211M USD +246%
Property, Plant and Equipment, Net 521K USD -6.46%
Operating Lease, Right-of-Use Asset 2.74M USD -27.7%
Other Assets, Noncurrent 96K USD -15.8%
Assets 215M USD +220%
Accounts Payable, Current 3.61M USD -4.35%
Employee-related Liabilities, Current 4.91M USD -2.44%
Accrued Liabilities, Current 13.3M USD -5.85%
Liabilities, Current 49.6M USD -26.5%
Operating Lease, Liability, Noncurrent 1.62M USD -45.9%
Liabilities 51.5M USD -31.6%
Retained Earnings (Accumulated Deficit) -611M USD -38.5%
Stockholders' Equity Attributable to Parent 163M USD
Liabilities and Equity 215M USD +220%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -6.64M USD +39%
Net Cash Provided by (Used in) Financing Activities -93K USD -100%
Net Cash Provided by (Used in) Investing Activities -23K USD +75.5%
Common Stock, Shares Authorized 50M shares +150%
Common Stock, Shares, Issued 10.9M shares +142%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -6.76M USD -144%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 196M USD +448%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD -100%
Deferred Tax Assets, Valuation Allowance 121M USD +45.5%
Deferred Tax Assets, Gross 122M USD +43.9%
Operating Lease, Liability 3M USD -26.5%
Payments to Acquire Property, Plant, and Equipment 23K USD -75.5%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -170M USD -641%
Lessee, Operating Lease, Liability, to be Paid 3.4M USD -32%
Property, Plant and Equipment, Gross 3.87M USD +3.15%
Operating Lease, Liability, Current 1.38M USD +27.4%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.73M USD +3.96%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.67M USD +4.06%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 394K USD -56.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.73M USD
Deferred Tax Assets, Operating Loss Carryforwards 46.7M USD +31.6%
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 12.9M USD +12%
Operating Lease, Payments 400K USD +33.3%
Deferred Tax Assets, Net of Valuation Allowance 782K USD -47.9%
Share-based Payment Arrangement, Expense 3.91M USD +27.6%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%